The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is a clinical trial that compares three highly effective, reversible methods of contraception—the progestogen-only injectable depot medroxyprogesterone acetate (DMPA), a progestogen implant called Jadelle, and the copper intrauterine device (IUD)—to evaluate whether there is any difference in the risk of HIV acquisition among women using these methods. The study will also compare side effects, pregnancy rates, and women’s patterns of use for the three contraceptive methods.
The following webinar from WHO/IBP Initiative is in preparation for the ECHO results expected mid-2019.
